Russell Investments Group Ltd. Purchases 76,350 Shares of Moderna, Inc. (NASDAQ:MRNA)

Russell Investments Group Ltd. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 81.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 170,243 shares of the company’s stock after purchasing an additional 76,350 shares during the quarter. Russell Investments Group Ltd.’s holdings in Moderna were worth $7,019,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB increased its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc acquired a new stake in Moderna in the 4th quarter valued at $37,000. Crowley Wealth Management Inc. bought a new stake in Moderna during the 4th quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

MRNA stock opened at $26.20 on Monday. The firm has a 50 day simple moving average of $31.56 and a two-hundred day simple moving average of $40.84. The stock has a market cap of $10.13 billion, a PE ratio of -2.82 and a beta of 2.23. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on MRNA shares. Royal Bank of Canada reissued a “sector perform” rating and set a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Evercore ISI set a $50.00 price target on Moderna in a research report on Friday, February 14th. UBS Group dropped their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Finally, Berenberg Bank upped their price objective on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.